A pilot study of alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia

Leuk Res. 1997 May;21(5):375-80. doi: 10.1016/s0145-2126(96)00108-7.


Thirteen patients with accelerated phase of chronic myeloid leukemia (CML-AC) were treated with intravenous plicamycin and subcutaneous alpha-interferon. Two patients stabilized, three patients had partial hematologic responses and one patient had a hematologic complete response with a major cytogenetic response. Two patients, progressing on hydroxyurea, did not respond, but demonstrated re-sensitization to hydroxyurea after completion of induction therapy and had prolonged return to chronic phase for 30 months and 25 months. Four non-responders subsequently received additional chemotherapy and responded. Median survival of all study patients from the development of accelerated phase of CML was 24 months: substantially longer than other reported series (median 6 months). Plicamycin appears to add efficacy to interferon in the stabilization of accelerated phase of CML.

Publication types

  • Clinical Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Antibiotics, Antineoplastic / administration & dosage
  • Antibiotics, Antineoplastic / therapeutic use*
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Biopsy
  • Bone Marrow / pathology
  • Drug Administration Schedule
  • Female
  • Humans
  • Hydroxyurea / therapeutic use
  • Infusions, Intravenous
  • Injections, Subcutaneous
  • Interferon-alpha / administration & dosage
  • Interferon-alpha / therapeutic use*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Male
  • Middle Aged
  • Pilot Projects
  • Plicamycin / administration & dosage
  • Plicamycin / therapeutic use*
  • Survival Rate


  • Antibiotics, Antineoplastic
  • Antineoplastic Agents
  • Interferon-alpha
  • Plicamycin
  • Hydroxyurea